Health
Emyria to seek approval for trial evaluating MDMA to treat PTSD – Stockhead
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder…
Link copied toclipboard
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder was rejected on ethics grounds, an ASX-listed drug development company is taking another crack at it.
Emyria (ASX:EMD) announced this morning that in partnership with Mind Medicine Australia it would seek approval for a major clinical trial testing the use of MDMA to alleviate treatment-resistant PTSD.
Emyria managing…
-
General11 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News23 hours agoCat-Sitting Leads to Chaos for Austin Butler in the Trailer for Darren Aronofsky’s New Crime-Thriller ‘Caught Stealing’
-
Noosa News22 hours agoIs Auckland New Zealand’s New Cultural Capital?
-
General21 hours agoThree maps that show the scale of the NSW flood disaster